logo_ProQR-150x150.png
ProQR to Present at Two Upcoming Conferences
April 03, 2018 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, the Netherlands, April 03, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
Malachite Logo 1.png
Vitality Biopharma Submits Orphan Drug Designation Request to FDA for Flagship THC Prodrug VITA-100
January 17, 2018 08:00 ET | Vitality Biopharma, Inc
LOS ANGELES, Jan. 17, 2018 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals,...
logo_ProQR-150x150.png
ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa
November 29, 2017 07:00 ET | ProQR Therapeutics N.V.
Key Updates ProQR’s drug candidate, QR-313 for dystrophic epidermolysis bullosa (DEB) receives orphan drug designation in the EU from the EMA.QR-313 also received U.S. ODD from the FDA in September...
logo_ProQR-150x150.png
ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis
September 25, 2017 16:00 ET | ProQR Therapeutics N.V.
Key updates QR-010 was observed to be safe and well-tolerated across all doses in this trial with no serious adverse events related to treatment.A clinically meaningful improvement of CF respiratory...
logo_ProQR-150x150.png
ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology
September 21, 2017 07:05 ET | ProQR Therapeutics N.V.
Key updates ProQR presents in vivo data in a relevant disease model, establishing proof of concept for its novel and proprietary Axiomer® RNA editing platform technology.Axiomer® technology Editing...
logo_ProQR-150x150.png
ProQR to Present at Two Investor Conferences in September
September 21, 2017 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Sept. 21, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that the Company will present at two investor conferences during the month of...
logo_ProQR-150x150.png
ProQR Receives Orphan Drug Designation from FDA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa and will Present Data at two Scientific Conferences
September 19, 2017 07:00 ET | ProQR Therapeutics N.V.
Key Updates ProQR’s drug candidate QR-313 for dystrophic epidermolysis bullosa (DEB) receives orphan drug designation from the FDA, representing the fifth program in the Company’s pipeline to receive...
logo_ProQR-150x150.png
ProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics
September 12, 2017 07:00 ET | ProQR Therapeutics N.V.
Key updates ProQR spins out CNS-focused company, Amylon Therapeutics, with seed funding from a group of institutional and private investors.As part of the transaction, ProQR has granted an exclusive...
logo_ProQR-150x150.png
ProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA
September 05, 2017 07:00 ET | ProQR Therapeutics N.V.
Key Updates ProQR’s drug candidate QRX-421 for Usher syndrome receives orphan drug designation from the FDA and EMA, representing the third candidate in the company’s ophthalmology pipeline and the...
logo_ProQR-150x150.png
ProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong
August 28, 2017 07:00 ET | ProQR Therapeutics N.V.
Key Updates ProQR appoints three new members to the Company’s Scientific Advisory Board: Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong, who bring a tremendous amount of experience in the...